Inve US ▾
SOSOLV

Solventum (SOLV) Q4 FY25 earnings call: guidance and Q&A

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 26, 2026

Source: earnings call transcript

Executive summary

Solventum Q4 FY25 — Strong Sales Growth and Accelerated Portfolio Optimization

Solventum closed its first full year as an independent company with strong Q4 FY25 organic sales growth, driven by MedSurg and Dental, and accelerated progress on portfolio optimization through the Acera acquisition and P&F divestiture. Despite gross margin and free cash flow headwinds in the quarter, the company exceeded full-year sales and restructuring savings targets, positioning it for continued momentum and margin expansion in FY26, supported by new product launches and the Transform for the Future program.

Highlights

5

  • Organic sales growth of 3.5% in Q4 FY25, driven by MedSurg and Dental.

  • Full-year 2025 organic sales growth of 3.3%, ahead of 2%-3% expectations.

  • Announced a $1 billion share repurchase program, which began executing in January.

  • Completed Solventum restructuring program, exceeding expectations and delivering $125 million in annualized savings.

  • Acquisition of Acera Surgical closed, opening the door to the fast-growth synthetic tissue market.

Concerns

5

  • Gross margins were 53.5% in Q4, a 230 basis point sequential reduction, reflecting higher logistics costs and manufacturing timing.

  • Adjusted operating income of $397 million, or an operating margin of 19.9%, was below expectations.

  • Free cash flow was $33 million in Q4, below expectations due to higher divestiture costs and ERP/DC cutover costs.

  • Full-year 2025 free cash flow was negative $10 million, below expectations of $150 million to $250 million.

  • Estimated full-year 2026 tariff impact of $100 million to $120 million.

Guidance & targets

CategoryTargetConfidence
Organic sales growth
2% to 3%
high materiality
High
Organic sales growth (excluding SKU exits)
3% to 4%
high materiality
High
Operating margins
21% to 21.5%
high materiality
High
Earnings per share
$6.40 to $6.60
high materiality
High
Free cash flow
approximately $200 million
high materiality
High
Capital expenditures
$400 million to $450 million
medium materiality
High
Effective tax rate
19.5% to 20.5%
medium materiality
High
Non-operating expenses
$300 million
medium materiality
High
Net interest expense
around $270 million
medium materiality
High
Long-range plan sales growth
4% to 5%
high materiality
High
Long-range plan operating margins
23% to 25%
high materiality
High
Long-range plan EPS CAGR
10%
high materiality
High
Long-range plan free cash flow conversion rate
above 80%
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
MedSurg
Solid performance in negative pressure wound therapy, supported by double-digit growth in Prevena and ongoing expansion of V.A.C. Peel and Place dressing. Infection Prevention and Surgical Solutions outpaced expectations, driven by strong business performance partially offset by reversal of first half volume timing and SKU rationalization.
Advanced Wound Care growth: 1.7%Infection Prevention and Surgical Solutions growth: 4.2%
$1.2 billion3.2% organic——
Dental Solutions
Growth was driven by core restoratives, benefiting from further back order improvement and strong demand for new products like Clinpro Clear and Filtek Easy Match. New product sales are driving the majority of underlying business growth.
$343 million5.9% organic——
Health Information Systems
Delivered another solid quarter, supported by revenue cycle management software solutions and performance management solutions. This growth more than offset expected declines in clinician productivity solutions, with strong automation and acceptance rates in autonomous coding.
$348 million3.2% organic——

SOLV operating KPIs by quarter

SOLV operating KPIs stated on its earnings calls, by fiscal quarter
KPIThis call Dec 2025 Q4 FY25 Mar 2026 Q1 FY26Change vs prior quarter
Distribution centers
55 Regarding supply chain, we've taken further steps to separate from 3M and have now reduced our distribution center network to 55 locations, progressing towards our goal of 45. Source: earnings call transcript
54 With further work to streamline our distribution centers, we are now down to 54 worldwide. Source: earnings call transcript
-1.8%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

ProductTypeDetails
V.A.C. Peel and Place dressingexpansion
Trio Test Sterilization productslaunch
Tegaderm CHGlaunch
Clinpro Clearlaunch
Filtek Easy Matchlaunch
360 Compassupdate
Autonomous Codingupdate

Deals & partnerships

Acera Surgical Tuck-in acquisition that opens the door to the fast-growth synthetic tissue market and complements existing technology categories. $725 million

Closed on December 23. Early integration efforts are off to a good start, focusing on sustaining and accelerating momentum.

Buyer of Purification and Filtration business (not named) Sale of Purification and Filtration business.

Activity continues to progress as planned with target completion at the end of 2027. Close collaboration to ensure business continuity for the buyer's integration efforts across nearly 200 transition service agreements.

Risks & headwinds

Tariff impact FY26

$100 million to $120 million for FY26; 65 bps in FY25

Mitigation:Programmatic savings, Transform for the Future program.

Higher logistics costs Q4 FY25

230 bps sequential reduction in Q4 gross margin

Mitigation:ERP and distribution center cutover mitigation efforts.

ERP and Distribution Center cutover costs Q4 FY25, ongoing into FY26

Impacted Q4 FCF; higher costs to support cutovers

Mitigation:Management of cutover processes.

Raw material cost step-up from 3M FY27

about a 100 basis point headwind

Mitigation:Working with 3M for a better solution; option to source from other chemical manufacturers due to IP ownership.

Tough Q1 FY26 sales comparison Q1 FY26

approximately 180 basis points of additional sales volume benefit in the prior year

Mitigation:None explicitly stated, but acknowledged as a known factor in guidance.

What to watch in Q1 FY26

ERP deployments completion

This year (FY26)
Current Over 40% of TSAs exited, ERP deployments continue to roll out
Target Complete

Why it matters

Completion of ERP deployments is crucial for operational independence and efficiency from 3M, impacting future cost structure and resource allocation.

The ERP deployments continue to roll out with a plan to be complete this year.

Find out whether SOLV delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked about one-time impacts on Q4 margins and the components of the 50-100 bps margin expansion for 2026, including the contribution from the $500M cost savings program.

Wayde McMillan explained that approximately 150 bps of Q4 gross margin impact was one-time due to separation activities. For 2026, margin expansion is driven by sales leverage, programmatic gross margin savings, and initial benefits from the Transform for the Future program, despite tariff headwinds.

“approximately 150 basis points of the cost in our gross margins was onetime in nature.”

asked by Travis Steed · answered by Wayde McMillan

2 min read 6 chapters

Detailed narrative

Q4 FY25 Performance Highlights

Solventum delivered solid Q4 sales growth with Dental Solutions and MedSurg outperforming expectations, contributing to a 3.5% organic sales increase. The company initiated a $1 billion share repurchase program in January and successfully closed the Acera Surgical acquisition, which is expected to enhance its portfolio in the fast-growth synthetic tissue market. Despite some headwinds, the quarter provided a solid foundation for the new fiscal year.

Full Year 2025 Achievements

In its first full year as an independent public company, Solventum made significant progress, including formalizing its long-range plan and prioritizing five growth drivers. The company built an experienced leadership team, revamped its innovation process, and restructured its global sales organization. Full-year organic sales growth reached 3.3%, exceeding initial guidance, and the Solventum restructuring program delivered $125 million in annualized savings at a lower total cost of $90 million.

Separation and Portfolio Optimization

Progress on the separation from 3M is on track, with over 40% of transition service agreements (TSAs) exited and approximately 90% expected to be complete by the end of 2026. ERP deployments are continuing with a plan to be complete this year. The Purification and Filtration (P&F) divestiture is progressing towards a target completion in late 2027, while the Acera Surgical acquisition is integrating well and expected to contribute meaningfully to reported growth.

HIS and AI Strategy

The Health Information Systems (HIS) business delivered another solid quarter, driven by revenue cycle management and autonomous coding. Management views AI as a significant opportunity, leveraging decades of proprietary algorithms (over 1 million) and vast datasets to enhance autonomous coding capabilities. This unique positioning allows Solventum to train AI in ways others cannot, reinforcing its leadership in AI-driven reimbursement coding.

2026 Outlook and Margin Expansion

For FY26, Solventum guides to 2%-3% organic sales growth (3%-4% excluding SKU impact) and operating margins of 21%-21.5%, representing 50-100 basis points of expansion. This expansion is anticipated despite an estimated $100 million to $120 million tariff headwind, driven by sales leverage, programmatic supply chain savings, and the new Transform for the Future program. Q1 FY26 is expected to be the lowest margin quarter due to tough comparisons and tariff impacts.

Capital Allocation and Share Repurchase

With a healthy balance sheet, Solventum is accelerating its capital allocation strategy. The $1 billion share repurchase program, initiated in January, aims to offset stock-based compensation dilution and provides flexibility for further buybacks. This move follows an accelerated debt paydown strategy post-spin, demonstrating a balanced approach to capital returns and M&A opportunities.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.